Data suggest that pharmacotherapy reduces the costs involved in fistula management (by reducing hospitalization) and also offers increased spontaneous closure rate. Further prospective studies focusing on the above parameters are needed to demonstrate the clinicoeconomic benefits.
No takes yet. Share an insight, caveat, or question.
Leandros et al. (2004) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: